A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer (PROTACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01676259|
Recruitment Status : Recruiting
First Posted : August 30, 2012
Last Update Posted : July 2, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable locally advanced pancreatic cancer combined with chemotherapy treatment.
- ORR at 6 months.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Ductal Adenocarcinoma Pancreatic Cancer||Drug: siG12D-LODER Drug: Gemcitabine+nab-Paclitaxel Drug: Folfirinox||Phase 2|
In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable LAPC combined with chemotherapy treatment (Gemcitabine+nab-Paclitaxel or Folfirinox or modified Folfirinox). This will be a study to assess the response rate of the siG12D-LODER in patients with unresectable or borderline resectable LAPC. The study is of a single arm design with one arm receiving siG12D-LODER + chemotherapy.
The investigational agent siG12D-LODER is a miniature biodegradable bio polymeric matrix that encompasses the drug, designed and produced by Silenseed Ltd. The implantation of LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
siG12D-LODER has been studied in the escalating dose Phase I study of 15 patients, and results showed high safety and tolerability profiles, with no single DLT.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer|
|Actual Study Start Date :||March 7, 2018|
|Estimated Primary Completion Date :||October 2022|
|Estimated Study Completion Date :||August 2023|
Experimental: siG12D-LODER + chemotherapy
Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox
The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
Other Name: Chemotherapy
Folfirinox or modified Folfirinox
Other Name: Chemotherapy
- ORR at 6 months [ Time Frame: One year ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
1. Subject must be 18 years of age or older at the time of signing the informed consent.
Type of Subject and Disease Characteristics
- Histologically or cytologically confirmed adenocarcinoma of the pancreas.
- Locally advanced pancreatic cancer stage III according to The American Joint Committee on Cancer (AJCC) and defined as T4, N (any) and M0, according to the three factors, T (tumor), N (node involvement), and M (metastases), of the National Comprehensive Cancer Network TNM classification.
- Allocated to receive one of the following chemotherapies: gemcitabine plus nab-paclitaxel, FOLFIRINOX or modified FOLFIRIONOX as first line treatment for pancreatic cancer.
- Have a target tumor that is accessible for intratumoral administration by EUS as determined by the radiologist/gastroenterologist performing the EUS intratumoral administration, according to The American Society for Gastrointestinal Endoscopy (ASGE) guidelines (https://www.asge.org/home/practice-support/guidelines).
Have measurable disease. Subject will have a histologically-confirmed disease and must have clinically and/or radiographically documented measurable primary disease according to RECIST v1.1. At least one site of disease must be unidimensionally measurable.
- Eastern Cooperative Oncology Group (ECOG) Performance Scale of ≤ 1.
Demonstrate adequate organ function as defined below:
- serum creatinine <1.6 mg/dL
- international normalized ratio (INR) < 1.5 U
- absolute neutrophil count (ANC) > 1.5 x 109/L
- platelets ≥ 100 x 109/L
- hemoglobin ≥ 9 mg/dL
- alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 5 times upper limit of normal (ULN)
- bilirubin ≤ 1.5 x ULN Sex
- Male and/or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Women of childbearing potential (WOCBP): a negative serum or urine pregnancy test during screening.
Subject of childbearing potential, if sexually active (both men and women) must agree to use a barrier method of contraception, from the time of administration of the first treatment and for at least 8 weeks after EOT visit day.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Subjects are excluded from the study if any of the following criteria apply:
- Subjects with resectable pancreatic cancer.
- Evidence of metastatic disease.
- Other malignancy that would interfere with the current intervention.
- Any evidence of ascites (beyond trace).
- Bulky celiac adenopathy (≥2.5 cm) or non-adenocarcinoma histology.
- Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancers from which the subject has been disease-free for at least 2 years.
- History of clinically significant coagulopathy.
- Major surgery, other than diagnostic surgery, within 4 weeks prior to study entry without complete recovery.
- New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 4 months prior to the first chemotherapy cycle Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
- Known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus.
- Females who are pregnant or breast-feeding.
Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study.
- Any prior therapy for the treatment of pancreatic malignancy (including chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational).
- Prior therapy with any hypoxic cytotoxic agent (hypoxia-targeting drugs). Prior/Concurrent Clinical Study Experience
Subjects who are participating or participated in an investigational drug or device study (within 28 days prior to study entry from the last study dose date).
- Unwillingness or inability to comply with the study protocol for any reason.
- Known allergy to sesame oil.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01676259
|Contact: Orit Pollack-Shragai, MSc, MBAemail@example.com|
|United States, New Jersey|
|Hackensack Meridian Health||Active, not recruiting|
|Hackensack, New Jersey, United States, 07601|
|United States, New York|
|The Mount Sinai Hospital||Recruiting|
|New York, New York, United States, 10029|
|Contact: Celina Ang, MD 212-824-8551 firstname.lastname@example.org|
|Contact: Christopher DiMaio, MD 212-241-7531 email@example.com|
|Principal Investigator: Celina Ang, MD|
|Principal Investigator: Christopher J DiMaio, MD|
|Memorial Sloan Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Eileen M O'Reilly, MD 646-888-4182 firstname.lastname@example.org|
|Contact: Anna M Varghese, MD 646-888-4308 VarghesA@mskcc.org|
|Principal Investigator: Eileen M. O'Reilly, MD|
|Principal Investigator: Anna M Varghese, MD|
|Principal Investigator: Mark A Schattner, MD|
|United States, Texas|
|MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Milind Javle, MD 713-792-5434 email@example.com|
|Contact: Manoop Bhutani, MD 1-713-792-2121 Manoop.Bhutani@mdanderson.org|
|Principal Investigator: Milind Javle, MD|
|Principal Investigator: Manoop Bhutani, MD|
|Rambam Medical Center||Recruiting|
|Haifa, Israel, 3525408|
|Contact: Valerya Semenysty, MD +972-4-7776419 firstname.lastname@example.org|
|Contact: Iyad Khamaysi, MD +972-4-7773626 email@example.com|
|Principal Investigator: Valerya Semenysty, MD|
|Sub-Investigator: Iyad Khamaysi, MD|
|Rabin Medical Center||Completed|
|Petah Tikva, Israel, 49102|
|Sheba Medical Center (Tel H'shomer)||Recruiting|
|Ramat Gan, Israel, 52621|
|Contact: Talia Golan, MD +972-3-5305338 Talia.Golan@sheba.health.gov.il|
|Contact: Maor Lahav, MD +972- 3-5305875 Maor.Lahav@sheba.health.gov.il|
|Principal Investigator: Talia Golan, MD|
|Sub-Investigator: Maor Lahav, MD|
|Sourasky MC (Ichilov) Tel Aviv Israel||Recruiting|
|Tel Aviv, Israel|
|Contact: Ravit Geva, M.D 972- 36973082 firstname.lastname@example.org|
|Contact: Adam Phillips, M.D email@example.com|
|Assaf Harofeh Medical Center||Active, not recruiting|
|Tzrifin, Israel, 70300|
|Principal Investigator:||Eileen M O'Reilly, MD||Memorial Sloan Kettering Cancer Center|
|Principal Investigator:||Talia Golan, MD||Sheba Medical Center|
|Responsible Party:||Silenseed Ltd|
|Other Study ID Numbers:||
|First Posted:||August 30, 2012 Key Record Dates|
|Last Update Posted:||July 2, 2021|
|Last Verified:||June 2021|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
RNA interference (RNAi)
Pancreatic ductal adenocarcinoma
Locally Advanced Pancreatic cancer
Non operable pancreatic ductal adenocarcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Endocrine System Diseases
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs